Cinoxacin
Risk Factor: CM
Class: ANTI-INFECTIVES
/ Urinary Germicides
Contents of this page:
Fetal Risk Summary
Breast Feeding Summary
References
Questions and Answers
Fetal Risk Summary
Cinoxacin is a synthetic, oral quinolone antibacterial agent indicated for the treatment of urinary tract infections. Its actions and uses are similar to nalidixic acid. No evidence of impaired fertility or fetal harm was observed in reproduction studies in rats and rabbits at doses up to 10 times the daily human dose (1).
It is not known if cinoxacin crosses the placenta. The molecular weight (about 262) is low enough, however, that transfer to the fetus should be expected.
No reports describing the use of cinoxacin during human pregnancy have been located. Because of the potential for cinoxacin-induced arthropathy in the fetus and newborn, the manufacturer recommends that it not be used in pregnancy (1).
Breast Feeding Summary
No reports describing the use of cinoxacin during human lactation have been located. In immature dogs, a single 250-mg/kg dose caused lameness secondary to cartilage lesions of the weight-bearing joints (1). Because of the potential for this type of toxicity in a nursing infant, the manufacturer recommends that it not be used in lactating women (1).
References
-
Product information. Cinobac. Oclassen Pharmaceuticals, 1998.
